GlobeNewswire News Room·2025-07-22 19:49Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, of the upcoming lead plaintiff deadline on August 11, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm or visiting their website [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by August 11, 2025, acting on behalf of other class members [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 and has been ranked highly for the number of securities class action settlements since 2013 [4]. Group 3: Case Allegations - The lawsuit alleges that Rocket Pharmaceuticals made misleading statements regarding the safety and clinical trial protocol of RP-A501, concealing serious adverse events, including participant deaths [5]. - It is claimed that these misleading statements led to artificially inflated prices for Rocket Pharmaceuticals securities, resulting in investor damages when the true information became public [5].